Xeris Biopharma Holdings Inc (NASDAQ: XERS) is 30.09% higher on its value in year-to-date trading and has touched a low of $1.69 and a high of $6.07 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The XERS stock was last observed hovering at around $4.31 in the last trading session, with the day’s gains setting it 0.1%.
Currently trading at $4.41, the stock is 0.26% and -1.60% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.12 million and changing 2.32% at the moment leaves the stock 29.70% off its SMA200. XERS registered 150.57% gain for a year compared to 6-month gain of 41.80%. The firm has a 50-day simple moving average (SMA 50) of $4.4816 and a 200-day simple moving average (SMA200) of $3.4002.
The stock witnessed a -21.67% loss in the last 1 month and extending the period to 3 months gives it a 27.09%, and is 9.70% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.50% over the week and 7.42% over the month.
Xeris Biopharma Holdings Inc (XERS) has around 394 employees, a market worth around $678.87M and $203.07M in sales. Fwd P/E is 36.37. Profit margin for the company is -27.00%. Distance from 52-week low is 160.95% and -27.35% from its 52-week high. The company has generated returns on investments over the last 12 months (-24.85%).
The EPS is expected to grow by 83.57% this year.
Xeris Biopharma Holdings Inc (XERS) Top Institutional Holders
207.0 institutions hold shares in Xeris Biopharma Holdings Inc (XERS), with institutional investors hold 44.12% of the company’s shares. The shares outstanding are 149.43M, and float is at 141.94M with Short Float at 13.42%. Institutions hold 42.34% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 10.33 million shares valued at $23.25 million. The investor’s holdings represent 6.9649% of the XERS Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 7.66 million shares valued at $17.23 million to account for 5.1615 of the shares outstanding. The other top investors are CAXTON CORP which holds 5.11 million shares representing 3.4469% and valued at over $11.51 million, while BIOIMPACT CAPITAL LLC holds 3.2563 of the shares totaling 4.83 million with a market value of $10.87 million.
Xeris Biopharma Holdings Inc (XERS) Insider Activity
The most recent transaction is an insider sale by Hecht Beth. SEC filings show that Hecht Beth sold 40,000 shares of the company’s common stock on Mar 20 ’25 at a price of $5.43 per share for a total of $0.22 million. Following the sale, the insider now owns 1.35 million shares.
Still, SEC filings show that on Aug 12 ’24, Schmid John P. (Director) acquired 4,515 shares at an average price of $2.25 for $10147.0. The insider now directly holds 25,200 shares of Xeris Biopharma Holdings Inc (XERS).
